{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:42:44Z","timestamp":1778560964957,"version":"3.51.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The management of adult relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL) remains a significant challenge, with patients presenting particularly poor historical outcomes. Novel immunotherapies, such as Blinatumomab and Inotuzumab, have revived the therapeutic landscape of R\/R B-ALL, but their optimal sequencing, toxicity management, and post-transplant integration remain unclear, particularly in real-world, resource-limited settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 33 adult patients with R\/R B-ALL treated between 2019 and 2023 at two major oncology centers in Romania.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Blinatumomab and Inotuzumab achieved complete remission rates of 47.6% and 90%, respectively, with measurable residual disease negativity in over 60% of responders. Inotuzumab was more effective in early relapses and cases with high disease burden, while Blinatumomab showed benefit in later relapses and post-transplant settings. Eleven patients were successfully bridged to allogeneic stem cell transplant, and four were treated for post-transplant relapse, demonstrating the feasibility of immunotherapy in both contexts. Sequential monoclonal antibody use yielded poor survival unless used as a bridge to curative therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings emphasize the need for individualized treatment selection, rational immunotherapy sequencing, and the development of predictive biomarkers to optimize outcomes and minimize toxicity. Further studies are needed to refine therapeutic algorithms and define such prognostic biomarkers, particularly in underfunded healthcare systems.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1684382","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:36:59Z","timestamp":1765348619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world patient outcomes with Blinatumomab and Inotuzumab in adult relapsed\/refractory B-cell acute lymphoblastic leukemia: a retrospective analysis from two Romanian oncology centers"],"prefix":"10.3389","volume":"16","author":[{"given":"Ion","family":"Antohe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Titieanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vlad Andrei","family":"Cianga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmin","family":"Minciun\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lin","family":"D\u0103n\u0103il\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina Daniela","family":"T\u0103nase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliu","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Drago\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Zlei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Men\u021bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anamaria","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Ciocoiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"D\u0103sc\u0103lescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2217\/imt-2015-0023","article-title":"Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia","volume":"8","author":"Alcharakh","year":"2016","journal-title":"Immunotherapy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","article-title":"Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"92","author":"Aldoss","year":"2017","journal-title":"Am. J. Hematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3324\/haematol.2024.286350","article-title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Algeri","year":"2025","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1182\/bloodadvances.2019001381","article-title":"Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab","volume":"4","author":"Badar","year":"","journal-title":"Blood Adv."},{"key":"B5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","article-title":"Real-world outcomes of adult B-Cell acute lymphocytic leukemia patients treated with inotuzumab ozogamicin","volume":"20","author":"Badar","year":"","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1097\/MPH.0000000000001789","article-title":"Combination therapy with chemotherapy, donor lymphocyte infusion with concurrent blinatumomab in relapsed\/refractory acute precursor B-Lymphoblastic leukemia","volume":"42","author":"Choi","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.seminhematol.2020.11.001","article-title":"Role of blinatumomab, inotuzumab, and CAR T-cells: which to choose and how to sequence for patients with relapsed disease","volume":"57","author":"Curran","year":"2020","journal-title":"Semin. Hematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","article-title":"Blinatumomab for first-line treatment of children and young persons with B-ALL","volume":"42","author":"Hodder","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ajh.25394","article-title":"Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin","volume":"94","author":"Jabbour","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"106283","DOI":"10.1016\/j.leukres.2019.106283","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1016\/j.clml.2024.12.016","article-title":"Inotuzumab ozogamicin as first-line therapy in acute lymphoblastic leukemia","volume":"25","author":"Jabbour","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Notuzumab ozogamicin Versus standard care for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ccr3.604","article-title":"Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant","volume":"4","author":"Khan","year":"2016","journal-title":"Clin. Case Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.clml.2020.06.011","article-title":"Debate: transplant is still necessary in the era of targeted cellular therapy for acute lymphoblastic leukemia","volume":"20","author":"Khazal","year":"2020","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of allogeneic stem cell transplantation after Inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"N\u00e4gele","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/hon.2886","article-title":"Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant","volume":"39","author":"Papayannidis","year":"2021","journal-title":"Hematol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/healthcare11142069","article-title":"Analysis of the healthcare system in Romania: a brief review","volume":"11","author":"Petre","year":"2023","journal-title":"Healthc. (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1159\/000492941","article-title":"Long-term molecular remission achieved by antibody Anti-CD22 and ponatinib in a patient affected by Ph\u2019+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: a case report","volume":"63","author":"Pirosa","year":"2018","journal-title":"Chemotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s12325-019-00991-w","article-title":"Indirect treatment comparison of inotuzumab ozogamicin Versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia","volume":"36","author":"Proskorovsky","year":"2019","journal-title":"Adv. Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12325-019-01169-0","article-title":"Response to letter to the editor regarding: indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Proskorovsky","year":"2020","journal-title":"Adv. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"520.e1","DOI":"10.1016\/j.jtct.2024.03.004","article-title":"Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s12325-019-0873-7","article-title":"Matching-adjusted indirect comparison of blinatumomab vs. inotuzumab ozogamicin for adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"36","author":"Song","year":"2019","journal-title":"Adv. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s12325-019-01168-1","article-title":"Letter to the editor regarding: indirect treatment comparison of inotuzumab ozogamicin Versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Song","year":"2020","journal-title":"Adv. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the acute leukemia working party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.bbmt.2019.04.010","article-title":"Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Stein","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"B37","first-page":"1","article-title":"Romania: health system review","volume":"18","author":"Vladescu","year":"2016","journal-title":"Health Syst. Transit"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1002\/cam4.2680","article-title":"Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"8","author":"Yoon","year":"2019","journal-title":"Cancer Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:37:00Z","timestamp":1765348620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1684382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":38,"alternative-id":["10.3389\/fphar.2025.1684382"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1684382","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1684382"}}